Our investments

Neovacs

Neovacs (Alternext: ALNEV), a spin-off from the Université Pierre & Marie Curie in Paris, is a biotechnology company focused on an active immunotherapy technology platform, with applications for auto-immune diseases and other chronic diseases. It was founded by Professor Daniel Zagury, MD, PhD, one of the best immunologists in the world.

Neovacs was listed on Alternext in April 2010. It was the first successful listing on the stock market in the French biotechnology sector since 2008. Truffle Capital sold its participation in Neovacs in 2015

www.neovacs.fr

First FinTech Closing
On the 15th of November 2017, Truffle has successfully completed the first closing of its institutional fund Truffle Financial Innovation Fund.
Premier closing FinTech
Le 15/11/2017, Truffle réalise le premier closing de son fonds institutionnel Truffle Financial Innovation Fund.
Premier closing FinTech
Le 15/11/2017, Truffle réalise le premier closing de son fonds institutionnel Truffle Financial Innovation Fund.